Get started
Author

Kei Amioka

Observed names: Amioka, Kei, K Amioka, 網岡, 慶
ORCID: 0000-0002-6658-5203
Observed ORCID: 0000-0002-6658-5203
OpenAlex ID: A5024763582
Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma
2021 · Yuwa Ando, Tomokazu Kawaoka, et al. · Oncology · 55
Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein
2021 · Yumi Kosaka, Tomoki Kimura, et al. · Liver Cancer · 45
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
2021 · Yuwa Ando, Tomokazu Kawaoka, et al. · Cancers · 41
PDF
Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma
2023 · Masami Yamauchi, Atsushi Ono, et al. · Communications Medicine · 38
PDF
Real-world efficacy and safety of durvalumab–tremelimumab as second-line systemic therapy after atezolizumab–bevacizumab in unresectable hepatocellular carcinoma
2024 · Ryoichi Miura, Atsushi Ono, et al. · Medicine · 21
Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
2023 · Shigeki Yano, Tomokazu Kawaoka, et al. · Cancers · 18
PDF
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
2022 · Yuwa Ando, Tomokazu Kawaoka, et al. · Liver Cancer · 18
PDF
Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein
2023 · Takahiro Kinami, Kei Amioka, et al. · Cancers · 13
PDF
Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
2021 · Shigeki Yano, Tomokazu Kawaoka, et al. · Medicine · 11
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
2022 · Kei Amioka, Tomokazu Kawaoka, et al. · Cancers · 10
PDF
The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment
2022 · Kenji Yamaoka, Kenichiro Kodama, et al. · PLoS ONE · 9
PDF
Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab
2023 · Chihiro Kikugawa, Shinsuke Uchikawa, et al. · Oncology · 8
Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma
2022 · Kei Amioka, Tomokazu Kawaoka, et al. · Cancers · 7
PDF
Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma—Consideration of the Locations of Target Lesions
2023 · Shigeki Yano, Tomoki Kimura, et al. · Cancers · 6
PDF
The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib
2023 · Kikugawa Chihiro, Tomokazu Kawaoka, et al. · Oncology · 6
Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy
2021 · Kei Amioka, Tomokazu Kawaoka, et al. · Oncology · 6
Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma
2021 · Kensuke Naruto, Tomokazu Kawaoka, et al. · Oncology · 5
Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study
2025 · Ko Hashimoto, Tomokazu Kawaoka, et al. · Liver Cancer · 4
PDF
Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model
2024 · Hikaru Nakahara, Atsushi Ono, et al. · JCO Clinical Cancer Informatics · 4
Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma
2024 · Takahiro Kinami, Shinsuke Uchikawa, et al. · Cancer Medicine · 4
PDF
Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices
2022 · Yuki Shirane, Eisuke Murakami, et al. · BMC Gastroenterology · 4
PDF
Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection
2022 · Kenichiro Kodama, Tomokazu Kawaoka, et al. · Journal of Gastroenterology · 4
Influence of dispersion slope on the diagnosis of liver fibrosis by the shear wave in metabolic dysfunction‐associated steatotic liver disease
2024 · Naoyuki Ueda, Sho Mokuda, et al. · Hepatology Research · 3
Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study
2022 · Kensuke Naruto, Tomokazu Kawaoka, et al. · BMC Gastroenterology · 3
PDF
Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
2021 · Yusuke Johira, Tomokazu Kawaoka, et al. · Liver Cancer · 3
Works count: 42
Citation count: 353
H-index: 10
I10-index: 10
Year
Topic
Type